This site is intended for U.S. residents only. For Novartis Worldwide, Click here

Mailing List


	Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only.

Study Description

Screening

Study Centers

Contact/Consent

Cystic Fibrosis

Cystic fibrosis (CF) is an inherited disease of the mucus and sweat glands, and mostly affects the lungs, pancreas, liver, intestines, sinuses, and sex organs. [Source: www.nhlbi.nih.gov]

Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial.

How to use this system:

The purpose of this system is to help connect interested study participants with clinical research centers. The following is a brief outline explaining the main steps involved in using this system. Please note that every step in this process is optional.

1. Select a clinical trial that you feel best suits your (or the      participant's) health condition.
2. Answer the screening questions to see if you (or the      participant) meet the preliminary qualifications for the study.      The answers to these questions are not retained by this      system.
3. Select a study center to contact for additional information      about the clinical trial.
4. Set up an account and agree to the terms of use for this      system.
5. Submit your information to the study center you selected.
6. The study center may contact you and may ask more      questions about your (or the participant's) eligibility for the      study. The study center may invite you (and the participant if      applicable) to travel to the study center for additional screening      tests. Novartis cannot guarantee that you will be contacted by      the study center.
7. If you are eligible to participate in the study, then you will be      required to sign an informed consent before enrolling in the      study. An informed consent is provided to you to help you      understand the clinical trial, the nature of the medical treatment      (if any), procedures and known risks involved, before you agree      to participate in the study.

For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy.

Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.

Cystic Fibrosis Study CTBM100C2302

Novartis Pharmaceuticals Corporation and Chiron Corporation are conducting a clinical research study to compare the safety and effectiveness of an investigational formulation, Tobramycin Inhalation Powder (TIP), compared to Tobramycin Inhalation Solution (TOBI®) for participants 6 years of age and older, that have Cystic Fibrosis and a lung infection caused by the bacteria Pseudomonas aeruginosa. The purpose of this clinical research study is to study how breathing in TIP twice a day compares to breathing in TOBI®. Tobramycin Inhalation Powder (TIP) is an “investigational formulation”, which means that it is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA). TOBI® is a drug that has been approved for sale in the United States by the U.S. Food and Drug Administration (FDA) for the treatment of Pseudomonas aeruginosa infections in Cystic Fibrosis patients.
Trial phase: Phase 3
Participation Duration: Participants will be required visit the study center approximately 12 times over a 25 week period.
Protocol Number: CTBM100C2302

	Site Map \| Contact Us \| Clinical Trial Search \| Mailing List \| Clinical Trial FAQs
	Participation FAQs \| Clinical Trials Glossary \| About Informed Consent
	Novartis Medical and Clinical Research

Clinical Trial Search

Cystic Fibrosis